Beam Therapeutics Inc. (BMV:BEAM)
Mexico · Delayed Price · Currency is MXN | Market Cap | 48.00B +57.9% |
| Revenue (ttm) | 2.73B +158.9% |
| Net Income | -1.51B |
| EPS | -14.64 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12 |
| Open | 454.00 |
| Previous Close | 454.00 |
| Day's Range | 454.00 - 454.00 |
| 52-Week Range | 309.00 - 655.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial numbers in USD Financial StatementsNews
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics Earnings release: Q2 2026
Beam Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Beam Therapeutics Quarterly report: Q2 2026
Beam Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics Slides: Conference presentation
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 9, 2026.
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging...
Beam Therapeutics Transcript: AGM 2026
The meeting featured the election of three directors, ratification of Deloitte as auditor, and approval of executive compensation, with all proposals passing. No shareholder questions were raised, and final vote results will be filed in a Form 8-K.
Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Base editing programs show strong efficacy and safety in hematology and liver diseases, with lead assets advancing toward regulatory filings and broader patient reach. Accelerated approval is supported by robust biomarker data, and pricing will reflect long-term value.
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Po...
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort ...
Beam Therapeutics Earnings release: Q1 2026
Beam Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Beam Therapeutics Quarterly report: Q1 2026
Beam Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Beam Therapeutics Proxy statement: Proxy filing
Beam Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Beam Therapeutics Proxy statement: Proxy filing
Beam Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
Beam Therapeutics Transcript: Study result
BEAM-302 demonstrated robust efficacy and safety in 29 AATD patients, achieving durable, protective AAT levels and significant reduction of mutant Z-AAT with a single 60 mg dose. The therapy restored physiologic AAT regulation and showed a favorable safety profile, supporting advancement to pivotal trials.
Beam Therapeutics Press release: Study result
Beam Therapeutics issued a press release on March 25, 2026, disclosing material business information to investors.
Beam Therapeutics Slides: Study result
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-u...
Beam Therapeutics Earnings Call Transcript: Q4 2025
Expanded liver-targeted pipeline with BEAM-304 for PKU, secured $500M in strategic financing, and extended cash runway into mid-2029. Preclinical data support rapid Phe reduction, and regulatory engagement enables adaptive trial designs for multiple mutations.
Beam Therapeutics Annual report: Q4 2025
Beam Therapeutics has published its Q4 2025 annual report on February 24, 2026.